- Dr. Andrew Hamer has been appointed Chief Medical Officer of Cardiol Therapeutics (CRDL), effective immediately
- Dr. Hamer will lead the research and development of the company’s clinical-stage products
- The company’s former CMO and co-founder, Dr. Eldon Smith, is retiring
- Dr. Smith will continue to serve the company as Chair of the Board of Directors
- Cardiol Therapeutics is focused on the research and clinical development of innovative anti-inflammatory therapies
- Cardiol Therapeutics (CRDL) is down 2.59 per cent and trading at C$4.51 per share
Dr. Andrew Hamer has been appointed Chief Medical Officer of Cardiol Therapeutics (CRDL), effective immediately.
The announcement follows the retirement of the company’s former CMO and co-founder, Dr. Eldon Smith.
Dr. Smith will move into a new role as Chair of the Board of Directors and as a company advisor.
Dr. Hamer has 30 years of industry experience, including 19 years practicing cardiology and internal medicine.
David Elsley, President and CEO of Cardiol Therapeutics, welcomed Dr. Hamer to the company and wished Dr. Smith well in his retirement.
“We are extremely pleased to have Andrew join our leadership team as we continue to advance our clinical development programs and promising basic research initiatives designed to explore additional therapeutic strategies to address inflammatory heart disease,” he said.
“On behalf of the entire Cardiol team and the Board of Directors, I would like to take this opportunity to thank Dr. Eldon Smith for his exceptional contributions to the company and for his many years of service that have helped position us for success. I wish Eldon good health and happiness in his well-earned retirement.”
Dr. Hamer will lead the research and development of the company’s clinical-stage products and will also guide the development of additional novel therapeutics in the company’s pipeline.
“I am excited to be joining Cardiol Therapeutics and look forward to working with the outstanding leadership team in progressing the clinical development of the Company’s promising therapies,” Dr. Hamer commented.
Cardiol Therapeutics is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease.
The company’s lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus.
Cardiol Therapeutics (CRDL) is down 2.59 per cent and trading at C$4.51 per share.
